MJ 15

11-mJ, 15-Hz single-frequency diode-pumped Q-switched Er, Yb:phosphate glass laser.[Pubmed:18049580]

Opt Lett. 2001 Aug 15;26(16):1262-4.

A single-frequency diode-pumped Q-switched Er, Yb:phosphate glass laser that oscillates at an eye-safe 1.54etam wavelength has been developed for use in coherent Doppler lidar. A maximum TEM(00)-mode Q-switched output energy of 10.9 mJ and a relatively long pulse width of 228 ns were obtained at a repetition rate of 15 Hz by use of a modified 2-m-long telescopic cavity. Frequency stability of as high as +/-1.9-MHz standard deviation and a side-mode suppression ratio of more than 30 dB were also achieved.

K(alpha) x-ray emission characterization of 100 Hz, 15 mJ femtosecond laser system with high contrast ratio.[Pubmed:20052295]

Appl Phys B. 2008 Dec 12;94(4):569-575.

We report K(alpha) x-ray production with a high energy (110 mJ per pulse at 800 nm before compression/15 mJ at 400 nm after compression), high repetition rate (100 Hz), and high pulse contrast (better than 10(-9) at 400 nm) laser system. To develop laser-based x-ray sources for biomedical imaging requires to use high-energy and high-power ultra-fast laser system where compression is achieved under vacuum. Using this type of laser system, we demonstrate long-term stability of the x-ray yield, conversion efficiency higher than 1.5 x 10(-5) with a Mo target, and the x-ray spot size close to the optical focal spot. This high-repetition K(alpha) x-ray source can be very useful for x-ray phase-contrast imaging.

Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.[Pubmed:20380831]

Eur J Pharmacol. 2010 Jul 10;637(1-3):178-85.

MJ15, a novel cannabinoid CB(1) receptor selective antagonist was discovered. In receptor binding assays, MJ15 displayed a high affinity for rat cannabinoid CB(1) receptor (K(i)=27.2 pM, and IC(50)=118.9 pM), but a much lower affinity for rat cannabinoid CB(2) receptor (only 46% inhibition at 10 microM). At the cellular level, the IC(50) values against activation of cannabinoid CB(1) and CB(2) receptors induced by Win55212-2 in specially designed EGFP-CB(1)_U2OS and EGFP-CB(2)_U2OS cells were 0.11 microM and >10 microM, respectively. In addition, MJ15 dose-dependently blocked Win55212-2 mediated increase of intracellular Ca(2+) levels in hippocampal cells and reversed the inhibitory effects of cannabinoid CB(1) receptor agonist on forskolin-stimulated adenylyl cyclase activity in CHO cells expressing the human cannabinoid CB(1) receptor. In animal experiments, MJ15 demonstrated remarkable effects from 20 to 40 mg/kg, including promoted the small intestine peristalsis in ICR mice and inhibited food intake and body weight increase in diet-induced obesity (DIO) rat and mouse. 40 mg/kg MJ15 significantly reduced food intake at initial 2 weeks of treatment, prevented the increase of body weight and adipose by 46% and 28% respectively in DIO rats, and reduced body weight and adipose gain by 70% and 23% respectively in early onset obesity DIO mice after 4 weeks treatment. Meanwhile, dyslipidemia were ameliorated in both models. Taken together the in vitro and in vivo data, MJ15 is demonstrated to be a potent and selective cannabinoid CB(1) receptor antagonist and holds a prominent potency in obesity and dyslipidemia treatment.